2022
Karo Pharma publishes prospectus relating to the rights issue and receives approval to change listing venue to Nasdaq First North Growth Market
Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South…
Karo Pharma resolves on a fully guaranteed rights issue of approximately SEK 2.5 billion and announces the terms of the rights issue
Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South…
Karo Pharma receives approval to delist the Company’s share from Nasdaq Stockholm in connection with the change of listing venue to Nasdaq First No...
Karo Pharma Aktiebolag (publ) (the “Company” or ”Karo Pharma”) announced in a press release on 9 March 2022 that Karo…
Karo Pharma applies for delisting of the Company’s shares from Nasdaq Stockholm, in connection with the change of listing venue to Nasdaq First Nor...
The Board of Directors of Karo Pharma Aktiebolag (publ) (the “Company” or “Karo Pharma”) has today decided to apply for…
Year-end report 2021
Q4, October – December · Revenues amounted to MSEK 762.0 (721.2), corresponding to an increase of +6% for the period.·…
Karo Pharma completes the acquisition of Sylphar International NV
Karo Pharma Aktiebolag (“Karo”) today announces that the previously announced acquisition of the Belgian fast-growing digital-first brand company Sylphar International…